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Poster Session I S225report the results of a single-center, prospective evaluation for IO
and its subsequent treatment in 147 allo HCT survivors. Adult
(.18 years) allo HCT recipients were eligible for this study if
(1) they had survived for $1 year post-HCT, (2) were in remis-
sion from their primary disease, (3) had no uncontrolled infection
or GVHD, (4) had no contraindication for MRI, (5) had ade-
quate blood counts and renal and hepatic function, and (6) had
significant IO. Patients were screened with serum ferritin, and
those with ferritin .1000 ng/mL underwent liver R2 MRI to es-
timate liver iron concentration (LIC, normal #1.8 mg/g). Signif-
icant IO was defined as LIC $5 mg/g. Based on physician and
patient preference, patients with significant IO were offered ob-
servation only, phlebotomy, or were enrolled on a pilot study
of deferasirox (if phlebotomy was not feasible [hemoglobin
\11 g/dL] or was refused). 23 patients had IO (LIC .1.8) and
16 had significant IO (LIC $5). Among patients with significant
IO, 69% had acute leukemia and 56% had received myeloabla-
tive conditioning. The median baseline LIC was 10.0 (range,
5.1-43). All patients were transfusion independent at enrollment.
Five patients received no treatment (median LIC 6.4), 8 under-
went phlebotomy (median LIC 13.1) and 3 received daily defer-
asirox 20 mg/kg/day for 6 months (median LIC 6.3). Two
patients had abnormal liver function tests and one patient each
had cirrhosis and unexplained heart failure; all four received
phlebotomy. Followup serum ferritin decreased spontaneously
in 4 patients on the observation arm (median ferritin, 1606 at
baseline to 1264 at followup); 1 also had followup MRI (LIC de-
creased from 6.4 to 2.3). Phlebotomy was well tolerated and no
patient needed ESA’s to facilitate phlebotomy. Deferasirox was
well tolerated and led to a decrease in LIC in all 3 patients
(baseline to 6 mo LIC: 6.3 to 2.8, 9.0 to 6.8, 19.9 to 8.8).
Mild adverse events were observed that did not require discontin-
uation of drug therapy. Phlebotomy is feasible in the majority of
allo HCT recipients who have survived for $1 year after HCT
and have significant IO. Iron levels may decrease with time with-
out any therapy in selected allo HCT survivors. Although the
numbers are small, deferasirox may be a safe and effective alter-
native for allo HCT survivors with IO who cannot undergo phle-
botomy.181
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Background:Large granular lymphocytes (LGLs) are amorpholog-
ically distinct but an immunophenotypically heterogeneous set of
lymphocytes of activated T- orNK cells that mediate non-MHC-re-
stricted cytotoxicity. LGL expansion following allogeneic hemato-
poietic stem cell transplantation (HSCT) has been reported
although its clinical relevance on transplant outcomes is not clear.
Moreover, precipitating factor evoking LGL expansion is unknown.
Methods: A total of 323 consecutive patients who received alloge-
neic HSCTs from HLA identical sibling donors between January
2000 andOctober 2007 at the PrincessMargaret Hospital, Toronto,
Canada, were included in the retrospective study. The patients’ char-
acteristics were: gender (male/female5 196/127); median age 49.5
yrs (range 17-71); stem cell source (PBSC/BM5 25172); condition-
ing (myeloablative/reduced intensity5 228/95). The definition of
LGL expansion is as follows: 1) increasing number of peripheral
blood lymphocyte counts$ 3.0109/L for at least 3 months, and
2) the predominance of LGLs in the peripheral blood smears.
Results: Out of 323 recipients, 64 cases (19.8%) showed LGL ex-
pansion after allogeneic hematopoietic stem cell transplantation
(HSCT). The median onset of LGL expansion was 306 days (95%C.I. 205-407 days). The 1- and 2-year(s) incidence of LGL expan-
sion was 14.46 2.2% and 22.06 2.8%.
Compared to the patients without LGL expansion, improved
transplant outcomes were observed in patients with LGL expan-
sion: better overall survival (2 years OS; 94.8% vs 60.3%,
p\0.001), lower non-relapse mortality (2 years NRM; 2.6% vs
23.4%, p\0.001) and lower relapse incidence (5.6% vs 29.5%,
p\0.001).
Three risk factors were identified for the development of LGL ex-
pansion such as CMV serostatus of recipient, CMV reactivation, and
occurrence of chronic GVHD. Higher incidence of LGL expansion
was noted 1) in recipient CMV IgG (+) group (CMV-R+) compared
to CMV-R- group regardless of CMV serostatus of donor (52/193
[27%] vs 11/128 [9%]; p\0.001); 2) in patients experiencing
CMV reactivation (43/140 [31%] vs 21/183 [11%]; p\0.001); 3)
in patients developing chronic GVHD (61/252 [24%] vs 2/55
[4%]; p5 0.02).
Conclusion: LGL expansion is not uncommon following alloge-
neic HSCT with HLA-identical sibling donors, and strongly as-
sociates with favorable transplant outcomes esp. in terms of non-
relapse mortality. Its association with chronic GVHD suggested
that expanded LGLs may mediate GVL effect after allogeneic
HSCT.182
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Bronchiolits Obliterans (BO) is the most frequent non-infec-
tious pulmonary complication post allogeneic stem cell transplant
(SCT) and is strongly correlated with cGVHD. BO remains
a major cause of late post SCT morbidity and mortality. Airflow
obstruction as detected by spirometry occurs late in BO, only
when widespread small airways disease is well established and
the process is more likely to be irreversible. The Multiple Breath
Nitrogen Washout (MBNW) test is a sensitive and reproducible
measure of peripheral airway function that is highly sensitive to
bronchiolitis in smokers with otherwise normal spirometry. Its
role in assessing peripheral airway dysfunction and early BO
post SCT has not been assessed. In a cross sectional study, 30
pts post SCT (mean age 47, 19-68 yrs) underwent standard spi-
rometric and lung volume testing together with measurements of
acinar (Sacin) and conductive (Scond) peripheral airway ventila-
tory heterogeneity and Lung Clearance Index (LCI) as assessed
by MBNW. Median time post SCT was 12 (3-73) mths, with
most pts receiving reduced intensity conditioning (17/30) for
acute leukemia (15/30). 50% had prior aGVHD, though no pts
had active aGVHD at the time of testing. 20/30 pts had
cGVHD, with 18 pts having active disease at the time of testing.
40% had moderate/severe cGVHD by NIH Consensus Criteria.
27% cohort had evidence of airway obstruction (FEV1/FVC
\70% predicted), while abnormal Sacin (.0.3L21) and Scond
(.0.04L21) affected 73% and 80% respectively. Sacin, Scond
and LCI were inversely correlated to FEV1% predicted while
Scond and LCI were correlated with RV/TLC% predicted. 1
pt with evidence of obstruction had normal Sacin, while 13 pts
with normal spirometry had abnormal Sacin. On univariate anal-
ysis, poorer FEV1/FVC%, Sacin, Scond and LCI measures were
strongly associated with days post transplant, but only Sacin
(p5 0.016) and Scond (p5 0.014) were significantly associated
with a diagnosis of cGVHD. Poorer Sacin was also correlated
with increasing severity of cGVHD (R25 0.48, p5 0.002). On
multivariate analysis only cGVHD (p5 0.01) remained an inde-
pendent predictor of abnormal Sacin. Peripheral airway function
appears to decline following SCT, and is strongly associated with
the development of cGVHD. Prospective studies are being
